Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Caspase 8 | 2 | 2018 | 92 | 1.36 | Why? |
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 127 | 1.34 | Why? |
| HIV Protease | 2 | 2018 | 86 | 0.86 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2021 | 290 | 0.86 | Why? |
| Apoptosis | 4 | 2018 | 2335 | 0.83 | Why? |
| HIV-1 | 4 | 2018 | 3365 | 0.77 | Why? |
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 40 | 0.73 | Why? |
| Cellular Microenvironment | 1 | 2017 | 55 | 0.71 | Why? |
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2017 | 47 | 0.71 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2018 | 249 | 0.65 | Why? |
| Protein Isoforms | 1 | 2017 | 347 | 0.64 | Why? |
| CD4-Positive T-Lymphocytes | 4 | 2018 | 4545 | 0.59 | Why? |
| Efficiency, Organizational | 1 | 2019 | 482 | 0.57 | Why? |
| Jurkat Cells | 3 | 2018 | 273 | 0.51 | Why? |
| Immunity, Herd | 1 | 2021 | 1011 | 0.50 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.46 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.43 | Why? |
| Biomedical Research | 2 | 2020 | 5270 | 0.40 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.38 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.35 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.31 | Why? |
| Academic Medical Centers | 1 | 2019 | 3088 | 0.31 | Why? |
| Virus Latency | 2 | 2017 | 251 | 0.29 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.28 | Why? |
| Venous Thromboembolism | 1 | 2021 | 4273 | 0.24 | Why? |
| Virus Replication | 3 | 2021 | 14331 | 0.24 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.23 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.21 | Why? |
| Hospital Administrators | 1 | 2019 | 50 | 0.19 | Why? |
| Bystander Effect | 1 | 2017 | 68 | 0.18 | Why? |
| Mycoplasma hominis | 1 | 2017 | 15 | 0.18 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.17 | Why? |
| Alternative Splicing | 1 | 2017 | 82 | 0.17 | Why? |
| Liver Failure, Acute | 1 | 2021 | 279 | 0.17 | Why? |
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2017 | 77 | 0.17 | Why? |
| Mycoplasma Infections | 1 | 2017 | 65 | 0.16 | Why? |
| Body Fluids | 1 | 2021 | 451 | 0.16 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.16 | Why? |
| Ethics, Research | 1 | 2020 | 328 | 0.16 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 694 | 0.15 | Why? |
| Infusions, Intravenous | 1 | 2020 | 1224 | 0.15 | Why? |
| Cells, Cultured | 2 | 2017 | 5835 | 0.15 | Why? |
| Genes, Reporter | 1 | 2017 | 472 | 0.15 | Why? |
| Blood Coagulation Tests | 1 | 2020 | 855 | 0.14 | Why? |
| Cell Death | 1 | 2017 | 536 | 0.14 | Why? |
| HeLa Cells | 1 | 2017 | 1303 | 0.13 | Why? |
| Enoxaparin | 1 | 2021 | 1064 | 0.13 | Why? |
| Quality Assurance, Health Care | 1 | 2019 | 596 | 0.13 | Why? |
| Promoter Regions, Genetic | 1 | 2017 | 823 | 0.13 | Why? |
| Protein Precursors | 1 | 2017 | 425 | 0.13 | Why? |
| Cell Membrane | 1 | 2017 | 743 | 0.12 | Why? |
| Vaccination Refusal | 1 | 2021 | 831 | 0.12 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.12 | Why? |
| Humans | 27 | 2021 | 930598 | 0.12 | Why? |
| Stem Cell Transplantation | 1 | 2017 | 531 | 0.12 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 526 | 0.12 | Why? |
| Early Diagnosis | 1 | 2021 | 2443 | 0.12 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.11 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.10 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| Ambulatory Care Facilities | 1 | 2021 | 2063 | 0.10 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 1510 | 0.09 | Why? |
| Cell Line, Tumor | 1 | 2017 | 3608 | 0.09 | Why? |
| Organizational Innovation | 1 | 2019 | 2468 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.09 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.08 | Why? |
| Research | 1 | 2020 | 2115 | 0.08 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.08 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.08 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.08 | Why? |
| Lung Transplantation | 1 | 2017 | 1554 | 0.07 | Why? |
| Liver Transplantation | 1 | 2021 | 2864 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.07 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.07 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.07 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.06 | Why? |
| Healthcare Disparities | 1 | 2021 | 3893 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Male | 11 | 2021 | 367725 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.06 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.06 | Why? |
| Viral Hepatitis Vaccines | 1 | 2021 | 58 | 0.05 | Why? |
| Haemophilus Vaccines | 1 | 2021 | 76 | 0.05 | Why? |
| Poliovirus Vaccines | 1 | 2021 | 85 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.05 | Why? |
| Infant | 2 | 2021 | 30274 | 0.05 | Why? |
| Chills | 1 | 2020 | 102 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Kidney Tubules, Proximal | 1 | 2021 | 178 | 0.05 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.05 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Female | 10 | 2021 | 380317 | 0.05 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Vaccines, Conjugate | 1 | 2021 | 328 | 0.05 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2021 | 282 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2021 | 1115 | 0.04 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.04 | Why? |
| Blood Pressure Determination | 1 | 2020 | 450 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Disease-Free Survival | 1 | 2021 | 1654 | 0.04 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.04 | Why? |
| Mass Spectrometry | 1 | 2021 | 1165 | 0.04 | Why? |
| Pneumococcal Vaccines | 1 | 2021 | 571 | 0.04 | Why? |
| Dysgeusia | 1 | 2020 | 524 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.03 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.03 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.03 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.03 | Why? |
| Aged | 5 | 2021 | 215776 | 0.03 | Why? |
| Neoplasms | 1 | 2021 | 17251 | 0.03 | Why? |
| Acute Lung Injury | 1 | 2021 | 904 | 0.03 | Why? |
| Immunization | 1 | 2021 | 2019 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Autopsy | 1 | 2021 | 3495 | 0.02 | Why? |
| Needs Assessment | 1 | 2020 | 2352 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2021 | 1956 | 0.02 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.02 | Why? |
| Tissue Donors | 1 | 2017 | 1679 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Adult | 5 | 2021 | 244371 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Influenza Vaccines | 1 | 2021 | 2941 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.01 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.01 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.01 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.01 | Why? |
| Transplant Recipients | 1 | 2017 | 4982 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
Badley's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(162)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(275)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_